Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: Biological implications and therapeutical use

Molecules

Volumn 20, Issue 4, 2015, Pages 6342-6388

  Chiodelli, Paola ^a   Bugatti, Antonella ^a   Urbinati, Chiara ^a   Rusnati, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Angiogenesis; Glycomic; Heparan sulfate proteoglycan; Heparin; Interactome

Indexed keywords

ANGIOGENESIS MODULATOR; HEPARIN; PROTEIN BINDING; PROTEOHEPARAN SULFATE;

ANGIOGENESIS; ANIMAL; DRUG EFFECTS; GLYCOBIOLOGY; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS MODULATING AGENTS; ANIMALS; GLYCOMICS; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING;

EID: 84928608339     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20046342     Document Type: Review

References (326)

1. Presta, M.; Dell'Era, P.; Mitola, S.; Moroni, E.; Ronca, R.; Rusnati, M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16, 159-178.
2. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
3. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
4. Plow, E.F.; Meller, J.; Byzova, T.V. Integrin function in vascular biology: A view from 2013. Curr. Opin. Hematol. 2014, 21, 241-247.
5. Dejana, E.; Giampietro, C. Vascular endothelial-cadherin and vascular stability. Curr. Opin. Hematol. 2012, 19, 218-223.
6. Rusnati, M.; Presta, M. Extracellular angiogenic growth factor interactions: An angiogenesis interactome survey. Endothelium 2006, 13, 93-111.
7. Montuori, N.; Ragno, P. Role of upa/upar in the modulation of angiogenesis. Chem. Immunol. Allergy 2014, 99, 105-122.
8. Kanda, S.; Miyata, Y.; Kanetake, H. Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via flt-1/vascular endothelial growth factor receptor-1: Possible involvement of c-akt. J. Biol. Chem. 2004, 279, 4007-4016.
9. Oommen, S.; Gupta, S.K.; Vlahakis, N.E. Vascular endothelial growth factor a (vegf-a) induces endothelial and cancer cell migration through direct binding to integrin α9β1: Identification of a specific α9β1 binding site. J. Biol. Chem. 2011, 286, 1083-1092.
10. Fuh, G.; Garcia, K.C.; de Vos, A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J. Biol. Chem. 2000, 275, 26690-26695.
11. Itoh, N.; Ornitz, D.M. Fibroblast growth factors: From molecular evolution to roles in development, metabolism and disease. J. Biochem. 2011, 149, 121-130.
12. Gong, S.G. Isoforms of receptors of fibroblast growth factors. J. Cell. Physiol. 2014, 229, 1887-1895.
13. Eswarakumar, V.P.; Lax, I.; Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16, 139-149.
14. Rusnati, M.; Tanghetti, E.; Dell'Era, P.; Gualandris, A.; Presta, M. Alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (fgf-2) in cultured endothelial cells. Mol. Biol. Cell 1997, 8, 2449-2461.
15. Rusnati, M.; Urbinati, C.; Tanghetti, E.; Dell'Era, P.; Lortat-Jacob, H.; Presta, M. Cell membrane gm1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proc. Natl. Acad. Sci. USA 2002, 99, 4367-4372.
16. West, D.C.; Rees, C.G.; Duchesne, L.; Patey, S.J.; Terry, C.J.; Turnbull, J.E.; Delehedde, M.; Heegaard, C.W.; Allain, F.; Vanpouille, C.; et al. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J. Biol. Chem. 2005, 280, 13457-13464.
17. Wake, H.; Mori, S.; Liu, K.; Takahashi, H.K.; Nishibori, M. Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay. Eur. J. Pharmacol. 2009, 623, 89-95.
18. Viji, R.I.; Kumar, V.B.; Kiran, M.S.; Sudhakaran, P.R. Angiogenic response of endothelial cells to heparin-binding domain of fibronectin. Int. J. Biochem. Cell Biol. 2008, 40, 215-226.
19. Vlodavsky, I.; Abboud-Jarrous, G.; Elkin, M.; Naggi, A.; Casu, B.; Sasisekharan, R.; Ilan, N. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol. Haemost. Thromb. 2006, 35, 116-127.
20. Hollborn, M.; Kohen, L.; Werschnik, C.; Tietz, L.; Wiedemann, P.; Bringmann, A. Activated blood coagulation factor x (fxa) induces angiogenic growth factor expression in human retinal pigment epithelial cells. Investig. Ophthalmol. Vis. Sci. 2012, 53, 5930-5939.
21. Pakala, R.; Watanabe, T.; Benedict, C.R. Induction of endothelial cell proliferation by angiogenic factors released by activated monocytes. Cardiovasc. Radiat. Med. 2002, 3, 95-101.
22. Clauss, M.; Grell, M.; Fangmann, C.; Fiers, W.; Scheurich, P.; Risau, W. Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: Functional analysis of the tumor necrosis factor receptors. FEBS Lett. 1996, 390, 334-338.
23. Charalambous, C.; Pen, L.B.; Su, Y.S.; Milan, J.; Chen, T.C.; Hofman, F.M. Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. Cancer Res. 2005, 65, 10347-10354.
24. Hong, K.H.; Ryu, J.; Han, K.H. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-a. Blood 2005, 105, 1405-1407.
25. Wempe, F.; Lindner, V.; Augustin, H.G. Basic fibroblast growth factor (bfgf) regulates the expression of the cc chemokine monocyte chemoattractant protein-1 (mcp-1) in autocrine-activated endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2471-2478.
26. Vrancken, K.; Vervaeke, P.; Balzarini, J.; Liekens, S. Viruses as key regulators of angiogenesis. Rev. Med. Virol. 2011, 21, 181-200.
27. Dezube, B.J. The role of human immunodeficiency virus-i in the pathogenesis of acquired immunodeficiency syndrome-related kaposi's sarcoma: The importance of an inflammatory and angiogenic milieu. Semin. Oncol. 2000, 27, 420-423.
28. Ensoli, B.; Gendelman, R.; Markham, P.; Fiorelli, V.; Colombini, S.; Raffeld, M.; Cafaro, A.; Chang, H.K.; Brady, J.N.; Gallo, R.C. Synergy between basic fibroblast growth factor and HIV-1 tat protein in induction of kaposi's sarcoma. Nature 1994, 371, 674-680.
29. Eggert, A.; Ikegaki, N.; Kwiatkowski, J.; Zhao, H.; Brodeur, G.M.; Himelstein, B.P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 2000, 6, 1900-1908.
30. Barthlen, W.; Flaadt, D.; Girgert, R.; Conzelmann, J.; Schweizer, P.; Zugmaier, G.; Buck, M.; Knabbe, C. Significance of heparin-binding growth factor expression on cells of solid pediatric tumors. J. Pediatr. Surg. 2003, 38, 1296-1304.
31. Bikfalvi, A.; Moenner, M.; Javerzat, S.; North, S.; Hagedorn, M. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem. Soc. Trans. 2011, 39, 1560-1564.
32. Xu, D.; Esko, J.D. Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 2014, 83, 129-157.
33. Lindahl, U.; Kjellen, L. Pathophysiology of heparan sulphate: Many diseases, few drugs. J. Intern. Med. 2013, 273, 555-571.
34. Esko, J.D.; Lindahl, U. Molecular diversity of heparan sulfate. J. Clin. Investig. 2001, 108, 169-173.
35. Aviezer, D.; Hecht, D.; Safran, M.; Eisinger, M.; David, G.; Yayon, A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994, 79, 1005-1013.
36. Hayashi, K.; Madri, J.A.; Yurchenco, P.D. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: An adhesion modulated by glycosaminoglycan. J. Cell Biol. 1992, 119, 945-959.
37. Rusnati, M.; Presta, M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int. J. Clin. Lab. Res. 1996, 26, 15-23.
38. Liu, J.; Pedersen, L.C. Anticoagulant heparan sulfate: Structural specificity and biosynthesis. Appl. Microbiol. Biotechnol. 2007, 74, 263-272.
39. Wong, H.; Schotz, M.C. The lipase gene family. J. Lipid Res. 2002, 43, 993-999.
40. Marcum, J.A.; Rosenberg, R.D. Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem. Biophys. Res. Commun. 1985, 126, 365-372.
41. Quinsey, N.S.; Greedy, A.L.; Bottomley, S.P.; Whisstock, J.C.; Pike, R.N. Antithrombin: In control of coagulation. Int. J. Biochem. Cell Biol. 2004, 36, 386-389.
42. Rusnati, M.; Oreste, P.; Zoppetti, G.; Presta, M. Biotechnological engineering of heparin/heparan sulphate: A novel area of multi-target drug discovery. Curr. Pharm. Des. 2005, 11, 2489-2499.
43. Zhang, W.; Swanson, R.; Izaguirre, G.; Xiong, Y.; Lau, L.F.; Olson, S.T. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005, 106, 1621-1628.
44. Sankaranarayanan, N.V.; Desai, U.R. Toward a robust computational screening strategy for identifying glycosaminoglycan sequences that display high specificity for target proteins. Glycobiology 2014, 24, 1323-1333.
45. Maccarana, M.; Casu, B.; Lindahl, U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 1994, 269, 3903-3903.
46. Mosier, P.D.; Krishnasamy, C.; Kellogg, G.E.; Desai, U.R. On the specificity of heparin/heparan sulfate binding to proteins. Anion-binding sites on antithrombin and thrombin are fundamentally different. PLoS ONE 2012, 7, e48632.
47. Kreuger, J.; Spillmann, D.; Li, J.P.; Lindahl, U. Interactions between heparan sulfate and proteins: The concept of specificity. J. Cell Biol. 2006, 174, 323-327.
48. Kayitmazer, A.B.; Quinn, B.; Kimura, K.; Ryan, G.L.; Tate, A.J.; Pink, D.A.; Dubin, P.L. Protein specificity of charged sequences in polyanions and heparins. Biomacromolecules 2010, 11, 3325-3331.
49. Rullo, A.; Nitz, M. Importance of the spatial display of charged residues in heparin-peptide interactions. Biopolymers 2010, 93, 290-298.
50. Nunes, Q.M.; Mournetas, V.; Lane, B.; Sutton, R.; Fernig, D.G.; Vasieva, O. The heparin-binding protein interactome in pancreatic diseases. Pancreatology 2013, 13, 598-604.
51. Robinson, C.J.; Mulloy, B.; Gallagher, J.T.; Stringer, S.E. Vegf165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by k5 lyase. J. Biol. Chem. 2006, 281, 1731-1740.
52. Nakamura, M.; Uehara, Y.; Asada, M.; Honda, E.; Nagai, N.; Kimata, K.; Suzuki, M.; Imamura, T. Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (fgf) 19 signaling via fgf receptor 4 and betaklotho. J. Biol. Chem. 2011, 286, 26418-26423.
53. Xu, Y.; Liu, Y.J.; Yu, Q. Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycans. J. Biol. Chem. 2004, 279, 41179-41188.
54. Soncin, F.; Strydom, D.J.; Shapiro, R. Interaction of heparin with human angiogenin. J. Biol. Chem. 1997, 272, 9818-9824.
55. Hauser, S.; Weich, H.A. A heparin-binding form of placenta growth factor (plgf-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993, 9, 259-268.
56. Feyzi, E.; Lustig, F.; Fager, G.; Spillmann, D.; Lindahl, U.; Salmivirta, M. Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor a chain. J. Biol. Chem. 1997, 272, 5518-5524.
57. Zou, P.; Zou, K.; Muramatsu, H.; Ichihara-Tanaka, K.; Habuchi, O.; Ohtake, S.; Ikematsu, S.; Sakuma, S.; Muramatsu, T. Glycosaminoglycan structures required for strong binding to midkine, a heparin-binding growth factor. Glycobiology 2003, 13, 35-42.
58. Iwamoto, R.; Mine, N.; Kawaguchi, T.; Minami, S.; Saeki, K.; Mekada, E. Hb-egf function in cardiac valve development requires interaction with heparan sulfate proteoglycans. Development 2010, 137, 2205-2214.
59. Sato, J.; Hasegawa, S.; Akaogi, K.; Yasumitsu, H.; Yamada, S.; Sugahara, K.; Miyazaki, K. Identification of cell-binding site of angiomodulin (agm/taf/mac25) that interacts with heparan sulfates on cell surface. J. Cell. Biochem. 1999, 75, 187-195.
60. Chiodelli, P.; Mitola, S.; Ravelli, C.; Oreste, P.; Rusnati, M.; Presta, M. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler. Thromb. Vasc. Biol. 2011, 31, e116-e127.
61. Rider, C.C. Heparin/heparan sulphate binding in the tgf-beta cytokine superfamily. Biochem. Soc. Trans. 2006, 34, 458-460.
62. Raiber, E.A.; Wilkinson, J.A.; Manetti, F.; Botta, M.; Deakin, J.; Gallagher, J.; Lyon, M.; Ducki, S.W. Novel heparin/heparan sulfate mimics as inhibitors of hgf/sf-induced met activation. Bioorg. Med. Chem. Lett. 2007, 17, 6321-6325.
63. Qiu, H.; Yang, B.; Pei, Z.C.; Zhang, Z.; Ding, K. Wss25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking bone morphogenetic protein (bmp)/smad/id1 signaling. J. Biol. Chem. 2010, 285, 32638-32646.
64. Fluhr, H.; Spratte, J.; Heidrich, S.; Ehrhardt, J.; Steinmuller, F.; Zygmunt, M. Heparin inhibits interferon-gamma signaling in human endometrial stromal cells by interference with the cellular binding of interferon-gamma. Fertil. Steril. 2011, 95, 1272-1277.
65. Spratte, J.; Meyer zu Schwabedissen, H.; Endlich, N.; Zygmunt, M.; Fluhr, H. Heparin inhibits tnf-alpha signaling in human endometrial stromal cells by interaction with nf-kappab. Mol. Hum. Reprod. 2013, 19, 227-236.
66. Liang, A.; Du, Y.; Wang, K.; Lin, B. Quantitative investigation of the interaction between granulocyte-macrophage colony-stimulating factor and heparin by capillary zone electrophoresis. J. Sep. Sci. 2006, 29, 1637-1641.
67. Pichert, A.; Samsonov, S.A.; Theisgen, S.; Thomas, L.; Baumann, L.; Schiller, J.; Beck-Sickinger, A.G.; Huster, D.; Pisabarro, M.T. Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. Glycobiology 2012, 22, 134-145.
68. Meissen, J.K.; Sweeney, M.D.; Girardi, M.; Lawrence, R.; Esko, J.D.; Leary, J.A. Differentiation of 3-o-sulfated heparin disaccharide isomers: Identification of structural aspects of the heparin ccl2 binding motif. J. Am. Soc. Mass Spectrom. 2009, 20, 652-657.
69. Suffee, N.; Hlawaty, H.; Meddahi-Pelle, A.; Maillard, L.; Louedec, L.; Haddad, O.; Martin, L.; Laguillier, C.; Richard, B.; Oudar, O.; et al. Rantes/ccl5-induced pro-angiogenic effects depend on ccr1, ccr5 and glycosaminoglycans. Angiogenesis 2012, 15, 727-744.
70. Seeger, F.H.; Rasper, T.; Fischer, A.; Muhly-Reinholz, M.; Hergenreider, E.; Leistner, D.M.; Sommer, K.; Manavski, Y.; Henschler, R.; Chavakis, E.; et al. Heparin disrupts the cxcr4/sdf-1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair. Circ. Res. 2012, 111, 854-862.
71. Rusnati, M.; Coltrini, D.; Oreste, P.; Zoppetti, G.; Albini, A.; Noonan, D.M.; d'Adda di Fagagna, F.; Giacca, M.; Presta, M. Interaction of HIV-1 tat protein with heparin. Role of the backbone structure, sulfation, and size. J. Biol. Chem. 1997, 272, 11313-11320.
72. Bugatti, A.; Giagulli, C.; Urbinati, C.; Caccuri, F.; Chiodelli, P.; Oreste, P.; Fiorentini, S.; Orro, A.; Milanesi, L.; D'Ursi, P.; et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: Identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J. Biol. Chem. 2013, 288, 1150-1161.
73. Lisboa, F.A.; Warren, J.; Sulkowski, G.; Aparicio, M.; David, G.; Zudaire, E.; Dveksler, G.S. Pregnancy-specific glycoprotein 1 induces endothelial tubulogenesis through interaction with cell surface proteoglycans. J. Biol. Chem. 2011, 286, 7577-7586.
74. Chang, S.Y.; Ko, H.J.; Heo, T.H.; Kang, C.Y. Heparan sulfate regulates the antiangiogenic activity of endothelial monocyte-activating polypeptide-II at acidic pH. Mol. Pharmacol. 2005, 67, 1534-1543.
75. Babic, A.M.; Kireeva, M.L.; Kolesnikova, T.V.; Lau, L.F. Cyr61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 1998, 95, 6355-6360.
76. Shao, R.; Hamel, K.; Petersen, L.; Cao, Q.J.; Arenas, R.B.; Bigelow, C.; Bentley, B.; Yan, W. Ykl-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009, 28, 4456-4468.
77. Benslimane-Ahmim, Z.; Poirier, F.; Delomenie, C.; Lokajczyk, A.; Grelac, F.; Galy-Fauroux, I.; Mohamedi, A.; Fischer, A.M.; Heymann, D.; Lutomski, D.; et al. Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis 2013, 16, 575-593.
78. Mosesson, M.W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost. 2005, 3, 1894-1904.
79. Ikeda, Y.; Aihara, K.; Yoshida, S.; Iwase, T.; Tajima, S.; Izawa-Ishizawa, Y.; Kihira, Y.; Ishizawa, K.; Tomita, S.; Tsuchiya, K.; et al. Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the amp-activated protein kinase-endothelial nitric-oxide synthase signaling pathway. J. Biol. Chem. 2012, 287, 34256-34263.
80. Xu, D.; Fuster, M.M.; Lawrence, R.; Esko, J.D. Heparan sulfate regulates vegf165- and vegf121-mediated vascular hyperpermeability. J. Biol. Chem. 2011, 286, 737-745.
81. Kalinina, J.; Dutta, K.; Ilghari, D.; Beenken, A.; Goetz, R.; Eliseenkova, A.V.; Cowburn, D.; Mohammadi, M. The alternatively spliced acid box region plays a key role in fgf receptor autoinhibition. Structure 2012, 20, 77-88.
82. Ibrahimi, O.A.; Zhang, F.; Hrstka, S.C.; Mohammadi, M.; Linhardt, R.J. Kinetic model for fgf, fgfr, and proteoglycan signal transduction complex assembly. Biochemistry 2004, 43, 4724-4730.
83. Powell, A.K.; Fernig, D.G.; Turnbull, J.E. Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex. J. Biol. Chem. 2002, 277, 28554-28563.
84. Olsen, S.K.; Ibrahimi, O.A.; Raucci, A.; Zhang, F.; Eliseenkova, A.V.; Yayon, A.; Basilico, C.; Linhardt, R.J.; Schlessinger, J.; Mohammadi, M. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl. Acad. Sci. USA 2004, 101, 935-940.
85. Loo, B.M.; Kreuger, J.; Jalkanen, M.; Lindahl, U.; Salmivirta, M. Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4. J. Biol. Chem. 2001, 276, 16868-16876.
86. Zhang, F.; Moniz, H.A.; Walcott, B.; Moremen, K.W.; Linhardt, R.J.; Wang, L. Characterization of the interaction between robo1 and heparin and other glycosaminoglycans. Biochimie 2013, 95, 2345-2353.
87. Faye, C.; Moreau, C.; Chautard, E.; Jetne, R.; Fukai, N.; Ruggiero, F.; Humphries, M.J.; Olsen, B.R.; Ricard-Blum, S. Molecular interplay between endostatin, integrins, and heparan sulfate. J. Biol. Chem. 2009, 284, 22029-22040.
88. Ballut, L.; Sapay, N.; Chautard, E.; Imberty, A.; Ricard-Blum, S. Mapping of heparin/heparan sulfate binding sites on alphavbeta3 integrin by molecular docking. J. Mol. Recognit. JMR 2013, 26, 76-85.
89. Kaur, S.; Kuznetsova, S.A.; Pendrak, M.L.; Sipes, J.M.; Romeo, M.J.; Li, Z.; Zhang, L.; Roberts, D.D. Heparan sulfate modification of the transmembrane receptor cd47 is necessary for inhibition of t cell receptor signaling by thrombospondin-1. J. Biol. Chem. 2011, 286, 14991-15002.
90. Brandt, S.; Krauel, K.; Gottschalk, K.E.; Renne, T.; Helm, C.A.; Greinacher, A.; Block, S. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: Towards in vitro prediction of antigenicity. Thromb. Haemost. 2014, 112, 53-64.
91. Poon, I.K.; Parish, C.R.; Hulett, M.D. Histidine-rich glycoprotein functions cooperatively with cell surface heparan sulfate on phagocytes to promote necrotic cell uptake. J. Leukoc. Biol. 2010, 88, 559-569.
92. Brown, K.J.; Parish, C.R. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 1994, 33, 13918-13927.
93. Ranjbaran, H.; Wang, Y.; Manes, T.D.; Yakimov, A.O.; Akhtar, S.; Kluger, M.S.; Pober, J.S.; Tellides, G. Heparin displaces interferon-gamma-inducible chemokines (ip-10, i-tac, and mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of t cells. Circulation 2006, 114, 1293-1300.
94. Sekiya, A.; Okano-Kosugi, H.; Yamazaki, C.M.; Koide, T. Pigment epithelium-derived factor (pedf) shares binding sites in collagen with heparin/heparan sulfate proteoglycans. J. Biol. Chem. 2011, 286, 26364-26374.
95. Troeberg, L.; Lazenbatt, C.; Anower, E.K.M.F.; Freeman, C.; Federov, O.; Habuchi, H.; Habuchi, O.; Kimata, K.; Nagase, H. Sulfated glycosaminoglycans control the extracellular trafficking and the activity of the metalloprotease inhibitor timp-3. Chem. Biol. 2014, 21, 1300-1309.
96. Hibino, S.; Shibuya, M.; Hoffman, M.P.; Engbring, J.A.; Hossain, R.; Mochizuki, M.; Kudoh, S.; Nomizu, M.; Kleinman, H.K. Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of cd44. Cancer Res. 2005, 65, 10494-10501.
97. Selbonne, S.; Azibani, F.; Iatmanen, S.; Boulaftali, Y.; Richard, B.; Jandrot-Perrus, M.; Bouton, M.C.; Arocas, V. In vitro and in vivo antiangiogenic properties of the serpin protease nexin-1. Mol. Cell. Biol. 2012, 32, 1496-1505.
98. Rijken, D.C.; de Munk, G.A.; Jie, A.F. Interaction of plasminogen activators and plasminogen with heparin: Effect of ionic strength. Thromb. Haemost. 1993, 70, 867-872.
99. D'Souza, S.; Yang, W.; Marchetti, D.; Muir, C.; Farach-Carson, M.C.; Carson, D.D. Hip/rpl29 antagonizes vegf and fgf2 stimulated angiogenesis by interfering with hs-dependent responses. J. Cell. Biochem. 2008, 105, 1183-1193.
100. Zhang, W.; Swanson, R.; Xiong, Y.; Richard, B.; Olson, S.T. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: Evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. J. Biol. Chem. 2006, 281, 37302-37310.
101. Frese, M.A.; Milz, F.; Dick, M.; Lamanna, W.C.; Dierks, T. Characterization of the human sulfatase sulf1 and its high affinity heparin/heparan sulfate interaction domain. J. Biol. Chem. 2009, 284, 28033-28044.
102. Zhao, H.; Liu, H.; Chen, Y.; Xin, X.; Li, J.; Hou, Y.; Zhang, Z.; Zhang, X.; Xie, C.; Geng, M.; et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006, 66, 8779-8787.
103. Liang, J.F.; Li, Y.; Yang, V.C. The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation. Thromb. Res. 2000, 97, 349-358.
104. Goretzki, L.; Lombardo, C.R.; Stallcup, W.B. Binding of the ng2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). J. Biol. Chem. 2000, 275, 28625-28633.
105. Plouet, J.; Moro, F.; Bertagnolli, S.; Coldeboeuf, N.; Mazarguil, H.; Clamens, S.; Bayard, F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 1997, 272, 13390-13396.
106. Wijelath, E.; Namekata, M.; Murray, J.; Furuyashiki, M.; Zhang, S.; Coan, D.; Wakao, M.; Harris, R.B.; Suda, Y.; Wang, L.; et al. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J. Cell. Biochem. 2010, 111, 461-468.
107. Cochran, S.; Li, C.P.; Ferro, V. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconj. J. 2009, 26, 577-587.
108. Gitay-Goren, H.; Soker, S.; Vlodavsky, I.; Neufeld, G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 1992, 267, 6093-6098.
109. Soker, S.; Goldstaub, D.; Svahn, C.M.; Vlodavsky, I.; Levi, B.Z.; Neufeld, G. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of vegf165 to its receptors. Biochem. Biophys. Res. Commun. 1994, 203, 1339-1347.
110. Norrby, K. 2.5 kda and 5.0 kda heparin fragments specifically inhibit microvessel sprouting and network formation in vegf165-mediated mammalian angiogenesis. Int. J. Exp. Pathol. 2000, 81, 191-198.
111. Tessler, S.; Rockwell, P.; Hicklin, D.; Cohen, T.; Levi, B.Z.; Witte, L.; Lemischka, I.R.; Neufeld, G. Heparin modulates the interaction of vegf165 with soluble and cell associated flk-1 receptors. J. Biol. Chem. 1994, 269, 12456-12461.
112. Kawada, A.; Hiura, N.; Tajima, S.; Takahara, H. Alginate oligosaccharides stimulate vegf-mediated growth and migration of human endothelial cells. Arch. Dermatol. Res. 1999, 291, 542-547.
113. Ono, K.; Hattori, H.; Takeshita, S.; Kurita, A.; Ishihara, M. Structural features in heparin that interact with vegf165 and modulate its biological activity. Glycobiology 1999, 9, 705-711.
114. Turnbull, J.E.; Fernig, D.G.; Ke, Y.; Wilkinson, M.C.; Gallagher, J.T. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J. Biol. Chem. 1992, 267, 10337-10341.
115. Migdal, M.; Huppertz, B.; Tessler, S.; Comforti, A.; Shibuya, M.; Reich, R.; Baumann, H.; Neufeld, G. Neuropilin-1 is a placenta growth factor-2 receptor. J. Biol. Chem. 1998, 273, 22272-22278.
116. Lyon, M.; Deakin, J.A.; Mizuno, K.; Nakamura, T.; Gallagher, J.T. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 1994, 269, 11216-11223.
117. Lyon, M.; Rushton, G.; Gallagher, J.T. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J. Biol. Chem. 1997, 272, 18000-18006.
118. Kaneda, N.; Talukder, A.H.; Ishihara, M.; Hara, S.; Yoshida, K.; Muramatsu, T. Structural characteristics of heparin-line domain required for interaction of midkine with embryonic neurons. Biochem. Biophys. Res. Commun. 1996, 220, 108-112.
119. Kishibe, J.; Yamada, S.; Okada, Y.; Sato, J.; Ito, A.; Miyazaki, K.; Sugahara, K. Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/angiomodulin that induces cord-like structures to ecv-304 human carcinoma cells. J. Biol. Chem. 2000, 275, 15321-15329.
120. Cole, C.L.; Rushton, G.; Jayson, G.C.; Avizienyte, E. Ovarian cancer cell heparan sulfate 6-o-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (egf)-like growth factor/egf receptor signaling. J. Biol. Chem. 2014, 289, 10488-10501.
121. Rusnati, M.; Tulipano, G.; Urbinati, C.; Tanghetti, E.; Giuliani, R.; Giacca, M.; Ciomei, M.; Corallini, A.; Presta, M. The basic domain in HIV-1 tat protein as a target for polysulfonated heparin-mimicking extracellular tat antagonists. J. Biol. Chem. 1998, 273, 16027-16037.
122. Spillmann, D.; Witt, D.; Lindahl, U. Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem. 1998, 273, 15487-15493.
123. Sadir, R.; Baleux, F.; Grosdidier, A.; Imberty, A.; Lortat-Jacob, H. Characterization of the stromal cell-derived factor-1alpha-heparin complex. J. Biol. Chem. 2001, 276, 8288-8296.
124. Lortat-Jacob, H.; Grimaud, J.A. Binding of interferon-gamma to heparan sulfate is restricted to the heparin-like domains and involves carboxylic - but not n-sulfated - groups. Biochim. Biophys. Acta 1992, 1117, 126-130.
125. Sweeney, M.D.; Yu, Y.; Leary, J.A. Effects of sulfate position on heparin octasaccharide binding to ccl2 examined by tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 2006, 17, 1114-1119.
126. Stringer, S.E.; Forster, M.J.; Mulloy, B.; Bishop, C.R.; Graham, G.J.; Gallagher, J.T. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha. Blood 2002, 100, 1543-1550.
127. De Paz, J.L.; Moseman, E.A.; Noti, C.; Polito, L.; von Andrian, U.H.; Seeberger, P.H. Profiling heparin-chemokine interactions using synthetic tools. ACS Chem. Biol. 2007, 2, 735-744.
128. Rusnati, M.; Coltrini, D.; Caccia, P.; Dell'Era, P.; Zoppetti, G.; Oreste, P.; Valsasina, B.; Presta, M. Distinct role of 2-o-, n-, and 6-o-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble fgf receptor-1. Biochem. Biophys. Res. Commun. 1994, 203, 450-458.
129. Uniewicz, K.A.; Ori, A.; Ahmed, Y.A.; Yates, E.A.; Fernig, D.G. Characterisation of the interaction of neuropilin-1 with heparin and a heparan sulfate mimetic library of heparin-derived sugars. Peer J. 2014, 2, e461.
130. Feitsma, K.; Hausser, H.; Robenek, H.; Kresse, H.; Vischer, P. Interaction of thrombospondin-1 and heparan sulfate from endothelial cells. Structural requirements of heparan sulfate. J. Biol. Chem. 2000, 275, 9396-9402.
131. Kreuger, J.; Matsumoto, T.; Vanwildemeersch, M.; Sasaki, T.; Timpl, R.; Claesson-Welsh, L.; Spillmann, D.; Lindahl, U. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J. 2002, 21, 6303-6311.
132. Blackhall, F.H.; Merry, C.L.; Lyon, M.; Jayson, G.C.; Folkman, J.; Javaherian, K.; Gallagher, J.T. Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. Biochem. J. 2003, 375, 131-139.
133. Naggi, A.; Casu, B.; Perez, M.; Torri, G.; Cassinelli, G.; Penco, S.; Pisano, C.; Giannini, G.; Ishai-Michaeli, R.; Vlodavsky, I. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded n-acetylation, and glycol splitting. J. Biol. Chem. 2005, 280, 12103-12113.
134. Carpentier, M.; Denys, A.; Allain, F.; Vergoten, G. Molecular docking of heparin oligosaccharides with hep-ii heparin-binding domain of fibronectin reveals an interplay between the different positions of sulfate groups. Glycoconj. J. 2014, 31, 161-169.
135. Rusnati, M.; Presta, M. Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance. Cytokine Growth Factor Rev. 2014, in press.
136. Eriksson, A.E.; Cousens, L.S.; Weaver, L.H.; Matthews, B.W. Three-dimensional structure of human basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 1991, 88, 3441-3445.
137. Ishihara, M.; Tyrrell, D.J.; Stauber, G.B.; Brown, S.; Cousens, L.S.; Stack, R.J. Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J. Biol. Chem. 1993, 268, 4675-4683.
138. Guimond, S.; Maccarana, M.; Olwin, B.B.; Lindahl, U.; Rapraeger, A.C. Activating and inhibitory heparin sequences for fgf-2 (basic fgf). Distinct requirements for fgf-1, fgf-2, and fgf-4. J. Biol. Chem. 1993, 268, 23906-23914.
139. Presta, M.; Leali, D.; Stabile, H.; Ronca, R.; Camozzi, M.; Moroni, E.; Nicoli, S.; Liekens, S.; Rusnati, M. Heparin derivatives and semisynthetic biotechnological heparins as angiogenesis inhibitors. Front. Med. Chem. 2005, 2, 371-391.
140. Horowitz, A.; Tkachenko, E.; Simons, M. Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J. Cell Biol. 2002, 157, 715-725.
141. Rusnati, M.; Urbinati, C.; Presta, M. Internalization of basic fibroblast growth factor (bfgf) in cultured endothelial cells: Role of the low affinity heparin-like bfgf receptors. J. Cell. Physiol. 1993, 154, 152-161.
142. Presta, M.; Maier, J.A.; Rusnati, M.; Ragnotti, G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J. Cell. Physiol. 1989, 140, 68-74.
143. Ribatti, D.; Leali, D.; Vacca, A.; Giuliani, R.; Gualandris, A.; Roncali, L.; Nolli, M.L.; Presta, M. In vivo angiogenic activity of urokinase: Role of endogenous fibroblast growth factor-2. J. Cell Sci. 1999, 112, 4213-4221.
144. Gospodarowicz, D.; Cheng, J. Heparin protects basic and acidic fgf from inactivation. J. Cell. Physiol. 1986, 128, 475-484.
145. Sommer, A.; Rifkin, D.B. Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J. Cell. Physiol. 1989, 138, 215-220.
146. Flaumenhaft, R.; Moscatelli, D.; Rifkin, D.B. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J. Cell Biol. 1990, 111, 1651-1659.
147. Casu, B.; Guerrini, M.; Naggi, A.; Perez, M.; Torri, G.; Ribatti, D.; Carminati, P.; Giannini, G.; Penco, S.; Pisano, C.; et al. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry 2002, 41, 10519-10528.
148. Klagsbrun, M.; Baird, A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 1991, 67, 229-231.
149. Coltrini, D.; Rusnati, M.; Zoppetti, G.; Oreste, P.; Grazioli, G.; Naggi, A.; Presta, M. Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem. J. 1994, 303, 583-590.
150. Krilleke, D.; Ng, Y.S.; Shima, D.T. The heparin-binding domain confers diverse functions of vegf-a in development and disease: A structure-function study. Biochem. Soc. Trans. 2009, 37, 1201-1206.
151. Thompson, L.D.; Pantoliano, M.W.; Springer, B.A. Energetic characterization of the basic fibroblast growth factor-heparin interaction: Identification of the heparin binding domain. Biochemistry 1994, 33, 3831-3840.
152. Rose, K.; Kriha, D.; Pallast, S.; Junker, V.; Klumpp, S.; Krieglstein, J. Basic fibroblast growth factor: Lysine 134 is essential for its neuroprotective activity. Neurochem. Int. 2007, 51, 25-31.
153. Pellegrini, L.; Burke, D.F.; von Delft, F.; Mulloy, B.; Blundell, T.L. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407, 1029-1034.
154. Iwasaki, W.; Nagata, K.; Hatanaka, H.; Inui, T.; Kimura, T.; Muramatsu, T.; Yoshida, K.; Tasumi, M.; Inagaki, F. Solution structure of midkine, a new heparin-binding growth factor. EMBO J. 1997, 16, 6936-6946.
155. Zhou, H.; Casas-Finet, J.R.; Heath Coats, R.; Kaufman, J.D.; Stahl, S.J.; Wingfield, P.T.; Rubin, J.S.; Bottaro, D.P.; Byrd, R.A. Identification and dynamics of a heparin-binding site in hepatocyte growth factor. Biochemistry 1999, 38, 14793-14802.
156. Merkulova-Rainon, T.; England, P.; Ding, S.; Demerens, C.; Tobelem, G. The n-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor. J. Biol. Chem. 2003, 278, 37400-37408.
157. Fazekas, K.; Janovics, A.; Dome, B.; Koska, P.; Albini, A.; Timar, J. Effect of hgf-like basic hexapeptides on angiogenesis. Microvasc. Res. 2001, 62, 440-444.
158. Mobius, K.; Nordsieck, K.; Pichert, A.; Samsonov, S.A.; Thomas, L.; Schiller, J.; Kalkhof, S.; Teresa Pisabarro, M.; Beck-Sickinger, A.G.; Huster, D. Investigation of lysine side chain interactions of interleukin-8 with heparin and other glycosaminoglycans studied by a methylation-nmr approach. Glycobiology 2013, 23, 1260-1269.
159. Lortat-Jacob, H.; Grimaud, J.A. Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the c-terminal part of the molecule. FEBS Lett. 1991, 280, 152-154.
160. McCaffrey, T.A.; Falcone, D.J.; Du, B. Transforming growth factor-beta 1 is a heparin-binding protein: Identification of putative heparin-binding regions and isolation of heparins with varying affinity for tgf-beta 1. J. Cell. Physiol. 1992, 152, 430-440.
161. Sebollela, A.; Cagliari, T.C.; Limaverde, G.S.; Chapeaurouge, A.; Sorgine, M.H.; Coelho-Sampaio, T.; Ramos, C.H.; Ferreira, S.T. Heparin-binding sites in granulocyte-macrophage colony-stimulating factor. Localization and regulation by histidine ionization. J. Biol. Chem. 2005, 280, 31949-31956.
162. Thompson, S.A.; Higashiyama, S.; Wood, K.; Pollitt, N.S.; Damm, D.; McEnroe, G.; Garrick, B.; Ashton, N.; Lau, K.; Hancock, N.; et al. Characterization of sequences within heparin-binding egf-like growth factor that mediate interaction with heparin. J. Biol. Chem. 1994, 269, 2541-2549.
163. Chakravarty, L.; Rogers, L.; Quach, T.; Breckenridge, S.; Kolattukudy, P.E. Lysine 58 and histidine 66 at the c-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding. J. Biol. Chem. 1998, 273, 29641-29647.
164. Hussain, S.A.; Piper, M.; Fukuhara, N.; Strochlic, L.; Cho, G.; Howitt, J.A.; Ahmed, Y.; Powell, A.K.; Turnbull, J.E.; Holt, C.E.; et al. A molecular mechanism for the heparan sulfate dependence of slit-robo signaling. J. Biol. Chem. 2006, 281, 39693-39698.
165. Brickman, Y.G.; Ford, M.D.; Small, D.H.; Bartlett, P.F.; Nurcombe, V. Heparan sulfates mediate the binding of basic fibroblast growth factor to a specific receptor on neural precursor cells. J. Biol. Chem. 1995, 270, 24941-24948.
166. Ori, A.; Free, P.; Courty, J.; Wilkinson, M.C.; Fernig, D.G. Identification of heparin-binding sites in proteins by selective labeling. Mol. Cell. Proteomics 2009, 8, 2256-2265.
167. Stahl, S.; Gaetzner, S.; Mueller, T.D.; Felbor, U. Endostatin phenylalanines 31 and 34 define a receptor binding site. Genes Cells 2005, 10, 929-939.
168. Levy-Adam, F.; Abboud-Jarrous, G.; Guerrini, M.; Beccati, D.; Vlodavsky, I.; Ilan, N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J. Biol. Chem. 2005, 280, 20457-20466.
169. Holloway, D.E.; Chavali, G.B.; Hares, M.C.; Subramanian, V.; Acharya, K.R. Structure of murine angiogenin: Features of the substrate- and cell-binding regions and prospects for inhibitor-binding studies. Acta Crystallogr. Sect. D Biol. Crystallogr. 2005, 61, 1568-1578.
170. Moroianu, J.; Riordan, J.F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. USA 1994, 91, 1677-1681.
171. Novotny, W.F.; Maffi, T.; Mehta, R.L.; Milner, P.G. Identification of novel heparin-releasable proteins, as well as the cytokines midkine and pleiotrophin, in human postheparin plasma. Arterioscler. Thromb. 1993, 13, 1798-1805.
172. Matsuda, Y.; Talukder, A.H.; Ishihara, M.; Hara, S.; Yoshida, K.; Muramatsu, T.; Kaneda, N. Limited proteolysis by chymotrypsin of midkine and inhibition by heparin binding. Biochem. Biophys. Res. Commun. 1996, 228, 176-181.
173. Deepa, S.S.; Yamada, S.; Zako, M.; Goldberger, O.; Sugahara, K. Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor. J. Biol. Chem. 2004, 279, 37368-37376.
174. Stabile, H.; Mitola, S.; Moroni, E.; Belleri, M.; Nicoli, S.; Coltrini, D.; Peri, F.; Pessi, A.; Orsatti, L.; Talamo, F.; et al. Bone morphogenic protein antagonist drm/gremlin is a novel proangiogenic factor. Blood 2007, 109, 1834-1840.
175. Yap, T.A.; Sandhu, S.K.; Alam, S.M.; de Bono, J.S. Hgf/c-met targeted therapeutics: Novel strategies for cancer medicine. Curr. Drug Targets 2011, 12, 2045-2058.
176. Rubin, J.S.; Day, R.M.; Breckenridge, D.; Atabey, N.; Taylor, W.G.; Stahl, S.J.; Wingfield, P.T.; Kaufman, J.D.; Schwall, R.; Bottaro, D.P. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling. J. Biol. Chem. 2001, 276, 32977-32983.
177. Ashikari, S.; Habuchi, H.; Kimata, K. Characterization of heparan sulfate oligosaccharides that bind to hepatocyte growth factor. J. Biol. Chem. 1995, 270, 29586-29593.
178. Salbach, P.B.; Bruckmann, M.; Turovets, O.; Kreuzer, J.; Kubler, W.; Walter-Sack, I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br. J. Clin. Pharmacol. 2000, 50, 221-226.
179. Zioncheck, T.F.; Richardson, L.; Liu, J.; Chang, L.; King, K.L.; Bennett, G.L.; Fugedi, P.; Chamow, S.M.; Schwall, R.H.; Stack, R.J. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J. Biol. Chem. 1995, 270, 16871-16878.
180. Kato, S.; Ishii, T.; Hara, H.; Sugiura, N.; Kimata, K.; Akamatsu, N. Hepatocyte growth factor immobilized onto culture substrates through heparin and matrigel enhances DNA synthesis in primary rat hepatocytes. Exp. Cell Res. 1994, 211, 53-58.
181. Urbinati, C.; Ravelli, C.; Tanghetti, E.; Belleri, M.; Giacopuzzi, E.; Monti, E.; Presta, M.; Rusnati, M. Substrate-immobilized hiv-1 tat drives vegfr2/alpha(v)beta(3)-integrin complex formation and polarization in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2012, 32, e25-e34.
182. Bugatti, A.; Chiodelli, P.; Rosenbluh, J.; Loyter, A.; Rusnati, M. Bsa conjugates bearing multiple copies of the basic domain of HIV-1 tat: Prototype for the development of multitarget inhibitors of extracellular tat. Antivir. Res. 2010, 87, 30-39.
183. Rusnati, M.; Urbinati, C.; Caputo, A.; Possati, L.; Lortat-Jacob, H.; Giacca, M.; Ribatti, D.; Presta, M. Pentosan polysulfate as an inhibitor of extracellular hiv-1 tat. J. Biol. Chem. 2001, 276, 22420-22425.
184. Rusnati, M.; Tulipano, G.; Spillmann, D.; Tanghetti, E.; Oreste, P.; Zoppetti, G.; Giacca, M.; Presta, M. Multiple interactions of HIV-I tat protein with size-defined heparin oligosaccharides. J. Biol. Chem. 1999, 274, 28198-28205.
185. Chang, H.C.; Samaniego, F.; Nair, B.C.; Buonaguro, L.; Ensoli, B. HIV-1 tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. Aids 1997, 11, 1421-1431.
186. Mitola, S.; Soldi, R.; Zanon, I.; Barra, L.; Gutierrez, M.I.; Berkhout, B.; Giacca, M.; Bussolino, F. Identification of specific molecular structures of human immunodeficiency virus type 1 tat relevant for its biological effects on vascular endothelial cells. J. Virol. 2000, 74, 344-353.
187. Albini, A.; Benelli, R.; Presta, M.; Rusnati, M.; Ziche, M.; Rubartelli, A.; Paglialunga, G.; Bussolino, F.; Noonan, D. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996, 12, 289-297.
188. Garcia-Olivas, R.; Hoebeke, J.; Castel, S.; Reina, M.; Fager, G.; Lustig, F.; Vilaro, S. Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans. Histochem. Cell Biol. 2003, 120, 371-382.
189. Raines, E.W.; Ross, R. Compartmentalization of pdgf on extracellular binding sites dependent on exon-6-encoded sequences. J. Cell Biol. 1992, 116, 533-543.
190. Rolny, C.; Spillmann, D.; Lindahl, U.; Claesson-Welsh, L. Heparin amplifies platelet-derived growth factor (pdgf)- bb-induced pdgf alpha -receptor but not pdgf beta-receptor tyrosine phosphorylation in heparan sulfate-deficient cells. Effects on signal transduction and biological responses. J. Biol. Chem. 2002, 277, 19315-19321.
191. Jakobsson, L.; van Meeteren, L.A. Transforming growth factor beta family members in regulation of vascular function: In the light of vascular conditional knockouts. Exp. Cell Res. 2013, 319, 1264-1270.
192. McCaffrey, T.A.; Falcone, D.J.; Vicente, D.; Du, B.; Consigli, S.; Borth, W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J. Cell. Physiol. 1994, 159, 51-59.
193. Vilchis-Landeros, M.M.; Montiel, J.L.; Mendoza, V.; Mendoza-Hernandez, G.; Lopez-Casillas, F. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem. J. 2001, 355, 215-222.
194. Niu, J.; Azfer, A.; Zhelyabovska, O.; Fatma, S.; Kolattukudy, P.E. Monocyte chemotactic protein (mcp)-1 promotes angiogenesis via a novel transcription factor, mcp-1-induced protein (mcpip). J. Biol. Chem. 2008, 283, 14542-14551.
195. Lau, E.K.; Paavola, C.D.; Johnson, Z.; Gaudry, J.P.; Geretti, E.; Borlat, F.; Kungl, A.J.; Proudfoot, A.E.; Handel, T.M. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: Implications for structure and function in vivo. J. Biol. Chem. 2004, 279, 22294-22305.
196. Yu, Y.; Sweeney, M.D.; Saad, O.M.; Crown, S.E.; Hsu, A.R.; Handel, T.M.; Leary, J.A. Chemokine-glycosaminoglycan binding: Specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry. J. Biol. Chem. 2005, 280, 32200-32208.
197. Ali, S.; Palmer, A.C.; Fritchley, S.J.; Maley, Y.; Kirby, J.A. Multimerization of monocyte chemoattractant protein-1 is not required for glycosaminoglycan-dependent transendothelial chemotaxis. Biochem. J. 2001, 358, 737-745.
198. Kawashima, H.; Watanabe, N.; Hirose, M.; Sun, X.; Atarashi, K.; Kimura, T.; Shikata, K.; Matsuda, M.; Ogawa, D.; Heljasvaara, R.; et al. Collagen xviii, a basement membrane heparan sulfate proteoglycan, interacts with l-selectin and monocyte chemoattractant protein-1. J. Biol. Chem. 2003, 278, 13069-13076.
199. Lortat-Jacob, H.; Baltzer, F.; Grimaud, J.A. Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. J. Biol. Chem. 1996, 271, 16139-16143.
200. Douglas, M.S.; Rix, D.A.; Dark, J.H.; Talbot, D.; Kirby, J.A. Examination of the mechanism by which heparin antagonizes activation of a model endothelium by interferon-gamma (ifn-gamma). Clin. Exp. Immunol. 1997, 107, 578-584.
201. Caccuri, F.; Giagulli, C.; Bugatti, A.; Benetti, A.; Alessandri, G.; Ribatti, D.; Marsico, S.; Apostoli, P.; Slevin, M.A.; Rusnati, M.; et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors cxcr1 and cxcr2. Proc. Natl. Acad. Sci. USA 2012, 109, 14580-14585.
202. De Francesco, M.A.; Baronio, M.; Poiesi, C. HIV-1 p17 matrix protein interacts with heparan sulfate side chain of CD44v3, syndecan-2, and syndecan-4 proteoglycans expressed on human activated CD4+ t cells affecting tumor necrosis factor alpha and interleukin 2 production. J. Biol. Chem. 2011, 286, 19541-19548.
203. Poiesi, C.; De Francesco, M.A.; Baronio, M.; Manca, N. HIV-1 p17 binds heparan sulfate proteoglycans to activated cd4(+) t cells. Virus Res. 2008, 132, 25-32.
204. Valdembri, D.; Serini, G.; Vacca, A.; Ribatti, D.; Bussolino, F. In vivo activation of jak2/stat-3 pathway during angiogenesis induced by gm-csf. FASEB J. 2002, 16, 225-227.
205. Wettreich, A.; Sebollela, A.; Carvalho, M.A.; Azevedo, S.P.; Borojevic, R.; Ferreira, S.T.; Coelho-Sampaio, T. Acidic ph modulates the interaction between human granulocyte-macrophage colony-stimulating factor and glycosaminoglycans. J. Biol. Chem. 1999, 274, 31468-31475.
206. Lantz, M.; Thysell, H.; Nilsson, E.; Olsson, I. On the binding of tumor necrosis factor (tnf) to heparin and the release in vivo of the tnf-binding protein i by heparin. J. Clin. Investig. 1991, 88, 2026-2031.
207. Tufvesson, E.; Westergren-Thorsson, G. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett. 2002, 530, 124-128.
208. Waters, J.P.; Pober, J.S.; Bradley, J.R. Tumour necrosis factor and cancer. J. Pathol. 2013, 230, 241-248.
209. Di Benedetto, M.; Starzec, A.; Vassy, R.; Perret, G.Y.; Crepin, M. Distinct heparin binding sites on vegf165 and its receptors revealed by their interaction with a non sulfated glycoaminoglycan (napac). Biochim. Biophys. Acta 2008, 1780, 723-732.
210. Park, M.; Lee, S.T. The fourth immunoglobulin-like loop in the extracellular domain of flt-1, a vegf receptor, includes a major heparin-binding site. Biochem. Biophys. Res. Commun. 1999, 264, 730-734.
211. Medeiros, V.P.; Paredes-Gamero, E.J.; Monteiro, H.P.; Rocha, H.A.; Trindade, E.S.; Nader, H.B. Heparin-integrin interaction in endothelial cells: Downstream signaling and heparan sulfate expression. J. Cell. Physiol. 2012, 227, 2740-2749.
212. Taraboletti, G.; Rusnati, M.; Ragona, L.; Colombo, G. Targeting tumor angiogenesis with tsp-1-based compounds: Rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 2010, 1, 662-673.
213. Ferrari do Outeiro-Bernstein, M.A.; Nunes, S.S.; Andrade, A.C.; Alves, T.R.; Legrand, C.; Morandi, V. A recombinant nh(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: A possible role for syndecan-4 proteoglycan. Matrix Biol. 2002, 21, 311-324.
214. Dias, J.V.; Benslimane-Ahmim, Z.; Egot, M.; Lokajczyk, A.; Grelac, F.; Galy-Fauroux, I.; Juliano, L.; le-Bonniec, B.; Takiya, C.M.; Fischer, A.M.; et al. A motif within the n-terminal domain of tsp-1 specifically promotes the proangiogenic activity of endothelial colony-forming cells. Biochem. Pharmacol. 2012, 84, 1014-1023.
215. Clamp, A.; Blackhall, F.H.; Henrioud, A.; Jayson, G.C.; Javaherian, K.; Esko, J.; Gallagher, J.T.; Merry, C.L. The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate. J. Biol. Chem. 2006, 281, 14813-14822.
216. Reis, R.C.; Schuppan, D.; Barreto, A.C.; Bauer, M.; Bork, J.P.; Hassler, G.; Coelho-Sampaio, T. Endostatin competes with bfgf for binding to heparin-like glycosaminoglycans. Biochem. Biophys. Res. Commun. 2005, 333, 976-983.
217. Rosenkilde, M.M.; Schwartz, T.W. The chemokine system - A major regulator of angiogenesis in health and disease. APMIS 2004, 112, 481-495.
218. Goger, B.; Halden, Y.; Rek, A.; Mosl, R.; Pye, D.; Gallagher, J.; Kungl, A.J. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: A model for chemokine regulation at inflammatory sites. Biochemistry 2002, 41, 1640-1646.
219. Hoogewerf, A.J.; Kuschert, G.S.; Proudfoot, A.E.; Borlat, F.; Clark-Lewis, I.; Power, C.A.; Wells, T.N. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997, 36, 13570-13578.
220. Whittall, C.; Kehoe, O.; King, S.; Rot, A.; Patterson, A.; Middleton, J. A chemokine self-presentation mechanism involving formation of endothelial surface microstructures. J. Immunol. 2013, 190, 1725-1736.
221. Halden, Y.; Rek, A.; Atzenhofer, W.; Szilak, L.; Wabnig, A.; Kungl, A.J. Interleukin-8 binds to syndecan-2 on human endothelial cells. Biochem. J. 2004, 377, 533-538.
222. Presta, M.; Belleri, M.; Vecchi, A.; Hesselgesser, J.; Mantovani, A.; Horuk, R. Noncompetitive, chemokine-mediated inhibition of basic fibroblast growth factor-induced endothelial cell proliferation. J. Biol. Chem. 1998, 273, 7911-7919.
223. Mercurius, K.O.; Morla, A.O. Cell adhesion and signaling on the fibronectin 1st type iii repeat; requisite roles for cell surface proteoglycans and integrins. BMC Cell Biol. 2001, 2, 18.
224. Fredenburgh, J.C.; Leslie, B.A.; Stafford, A.R.; Lim, T.; Chan, H.H.; Weitz, J.I. Zn2+ mediates high affinity binding of heparin to the alphac domain of fibrinogen. J. Biol. Chem. 2013, 288, 29394-29402.
225. Ushiro, S.; Ono, M.; Izumi, H.; Kohno, K.; Taniguchi, N.; Higashiyama, S.; Kuwano, M. Heparin-binding epidermal growth factor-like growth factor: P91 activation induction of plasminogen activator/inhibitor, and tubular morphogenesis in human microvascular endothelial cells. Jpn. J. Cancer Res. Gann 1996, 87, 68-77.
226. Gorsi, B.; Liu, F.; Ma, X.; Chico, T.J.; Shrinivasan, A.; Kramer, K.L.; Bridges, E.; Monteiro, R.; Harris, A.L.; Patient, R.; et al. The heparan sulfate editing enzyme Sulf1 plays a novel role in zebrafish VegfA mediated arterial venous identity. Angiogenesis 2014, 17, 77-91.
227. Ji, W.; Yang, J.; Wang, D.; Cao, L.; Tan, W.; Qian, H.; Sun, B.; Qian, Q.; Yin, Z.; Wu, M.; et al. Hsulf-1 gene exhibits anticancer efficacy through negatively regulating vegfr-2 signaling in human cancers. PLoS ONE 2011, 6, e23274.
228. Neufeld, G.; Gospodarowicz, D. Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor. J. Cell. Physiol. 1987, 132, 287-294.
229. Rusnati, M.; Dell'Era, P.; Urbinati, C.; Tanghetti, E.; Massardi, M.L.; Nagamine, Y.; Monti, E.; Presta, M. A distinct basic fibroblast growth factor (fgf-2)/fgf receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells. Mol. Biol. Cell 1996, 7, 369-381.
230. Taylor, S.; Folkman, J. Protamine is an inhibitor of angiogenesis. Nature 1982, 297, 307-312.
231. Olsson, A.K.; Larsson, H.; Dixelius, J.; Johansson, I.; Lee, C.; Oellig, C.; Bjork, I.; Claesson-Welsh, L. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res. 2004, 64, 599-605.
232. Miao, R.Q.; Chen, V.; Chao, L.; Chao, J. Structural elements of kallistatin required for inhibition of angiogenesis. Am. J. Physiol. Cell Physiol. 2003, 284, C1604-C1613.
233. Vanwildemeersch, M.; Olsson, A.K.; Gottfridsson, E.; Claesson-Welsh, L.; Lindahl, U.; Spillmann, D. The anti-angiogenic his/pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner. J. Biol. Chem. 2006, 281, 10298-10304.
234. Luster, A.D.; Greenberg, S.M.; Leder, P. The ip-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 1995, 182, 219-231.
235. Maurer, A.M.; Han, Z.C.; Dhermy, D.; Briere, J. Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate. J. Lab. Clin. Med. 1996, 127, 382-390.
236. Chadderton, N.S.; Stringer, S.E. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. Int. J. Biochem. Cell Biol. 2003, 35, 1052-1055.
237. Gengrinovitch, S.; Greenberg, S.M.; Cohen, T.; Gitay-Goren, H.; Rockwell, P.; Maione, T.E.; Levi, B.Z.; Neufeld, G. Platelet factor-4 inhibits the mitogenic activity of vegf121 and vegf165 using several concurrent mechanisms. J. Biol. Chem. 1995, 270, 15059-15065.
238. Kinsella, M.G.; Tsoi, C.K.; Jarvelainen, H.T.; Wight, T.N. Selective expression and processing of biglycan during migration of bovine aortic endothelial cells. The role of endogenous basic fibroblast growth factor. J. Biol. Chem. 1997, 272, 318-325.
239. Vlodavsky, I.; Korner, G.; Ishai-Michaeli, R.; Bashkin, P.; Bar-Shavit, R.; Fuks, Z. Extracellular matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 1990, 9, 203-226.
240. Cummings, R.D. The repertoire of glycan determinants in the human glycome. Mol. BioSyst. 2009, 5, 1087-1104.
241. Rek, A.; Krenn, E.; Kungl, A.J. Therapeutically targeting protein-glycan interactions. Br. J. Pharmacol. 2009, 157, 686-694.
242. Lin, X.; Takahashi, K.; Campion, S.L.; Liu, Y.; Gustavsen, G.G.; Pena, L.A.; Zamora, P.O. Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo. Int. J. Mol. Med. 2006, 17, 833-839.
243. Lee, T.Y.; Folkman, J.; Javaherian, K. Hspg-binding peptide corresponding to the exon 6a-encoded domain of vegf inhibits tumor growth by blocking angiogenesis in murine model. PLoS ONE 2010, 5, e9945.
244. Hamma-Kourbali, Y.; Bernard-Pierrot, I.; Heroult, M.; Dalle, S.; Caruelle, D.; Milhiet, P.E.; Fernig, D.G.; Delbe, J.; Courty, J. Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its c-thrombospondin repeat-i domain. J. Cell. Physiol. 2008, 214, 250-259.
245. Mader, J.S.; Smyth, D.; Marshall, J.; Hoskin, D.W. Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. Am. J. Pathol. 2006, 169, 1753-1766.
246. Lippi, G.; Favaloro, E.J. Recombinant platelet factor 4: A therapeutic, anti-neoplastic chimera? Semin. Thromb. Hemost. 2010, 36, 558-569.
247. Zhang, L.; Parry, G.C.; Levin, E.G. Inhibition of tumor cell migration by LD22-4, an N-terminal fragment of 24-kDa FGF2, is mediated by neuropilin 1. Cancer Res. 2013, 73, 3316-3325.
248. Roy, S.; Lai, H.; Zouaoui, R.; Duffner, J.; Zhou, H.; L, P.J.; Zhao, G.; Ganguly, T.; Kishimoto, T.K.; Venkataraman, G. Bioactivity screening of partially desulfated low-molecular-weight heparins: A structure/activity relationship study. Glycobiology 2011, 21, 1194-1205.
249. Zhao, W.; McCallum, S.A.; Xiao, Z.; Zhang, F.; Linhardt, R.J. Binding affinities of vascular endothelial growth factor (vegf) for heparin-derived oligosaccharides. Biosci. Rep. 2011, 32, 71-81.
250. Kim, J.; Al-Hilal, T.A.; Chung, S.W.; Kim, S.Y.; Ryu, G.H.; Son, W.C.; Byun, Y. Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention. J. Control. Release 2015, 199, 122-131.
251. Chung, S.W.; Bae, S.M.; Lee, M.; Al-Hilal, T.A.; Lee, C.K.; Kim, J.K.; Kim, I.S.; Kim, S.Y.; Byun, Y. Lht7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking vegf, fgf2 and pdgf-b signaling pathways. Biomaterials 2014, 37C, 271-278.
252. Pisano, C.; Aulicino, C.; Vesci, L.; Casu, B.; Naggi, A.; Torri, G.; Ribatti, D.; Belleri, M.; Rusnati, M.; Presta, M. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic vegf antagonist. Glycobiology 2005, 15, 1C-6C.
253. Basappa; Murugan, S.; Kavitha, C.V.; Purushothaman, A.; Nevin, K.G.; Sugahara, K.; Rangappa, K.S. A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to vegf, hb-egf, and tnf-alpha. Cancer Lett. 2010, 297, 231-243.
254. Cheng, J.J.; Huang, N.K.; Chang, T.T.; Wang, D.L.; Lu, M.K. Study for anti-angiogenic activities of polysaccharides isolated from antrodia cinnamomea in endothelial cells. Life Sci. 2005, 76, 3029-3042.
255. Koyanagi, S.; Tanigawa, N.; Nakagawa, H.; Soeda, S.; Shimeno, H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem. Pharmacol. 2003, 65, 173-179.
256. Hamma-Kourbali, Y.; Vassy, R.; Starzec, A.; Le Meuth-Metzinger, V.; Oudar, O.; Bagheri-Yarmand, R.; Perret, G.; Crepin, M. Vascular endothelial growth factor 165 (vegf(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to vegf(165) and vegf(165).Kdr complexes. J. Biol. Chem. 2001, 276, 39748-39754.
257. Liu, L.; Li, C.; Cochran, S.; Jimmink, S.; Ferro, V. Synthesis of a heparan sulfate mimetic library targeting fgf and vegf via click chemistry on a monosaccharide template. ChemMedChem 2012, 7, 1267-1275.
258. Maynard, H.D.; Hubbell, J.A. Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Acta Biomater. 2005, 1, 451-459.
259. Lake, A.C.; Vassy, R.; Di Benedetto, M.; Lavigne, D.; Le Visage, C.; Perret, G.Y.; Letourneur, D. Low molecular weight fucoidan increases vegf165-induced endothelial cell migration by enhancing vegf165 binding to vegfr-2 and nrp1. J. Biol. Chem. 2006, 281, 37844-37852.
260. Rezzola, S.; Monte, M.D.; Belleri, M.; Bugatti, A.; Chiodelli, P.; Corsini, M.; Cammalleri, M.; Cancarini, A.; Morbidelli, L.; Oreste, P.; et al. Therapeutic potential of anti-angiogenic multi-target n,o-sulfated E. Coli k5 polysaccharide in diabetic retinopathy. Diabetes 2015, doi:10.2337/db14-1378.
261. Casu, B.; Guerrini, M.; Guglieri, S.; Naggi, A.; Perez, M.; Torri, G.; Cassinelli, G.; Ribatti, D.; Carminati, P.; Giannini, G.; et al. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J. Med. Chem. 2004, 47, 838-848.
262. Garg, H.G.; Mrabat, H.; Yu, L.; Hales, C.A.; Li, B.; Moore, C.N.; Zhang, F.; Linhardt, R.J. Anti-proliferative effects of o-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells. Glycoconj. J. 2011, 28, 419-426.
263. Kasbauer, C.W.; Paper, D.H.; Franz, G. Sulfated beta-(1 - >4)-galacto-oligosaccharides and their effect on angiogenesis. Carbohydr. Res. 2001, 330, 427-430.
264. Foxall, C.; Wei, Z.; Schaefer, M.E.; Casabonne, M.; Fugedi, P.; Peto, C.; Castellot, J.J., Jr.; Brandley, B.K. Sulfated malto-oligosaccharides bind to basic fgf, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation. J. Cell. Physiol. 1996, 168, 657-667.
265. Giraux, J.L.; Matou, S.; Bros, A.; Tapon-Bretaudiere, J.; Letourneur, D.; Fischer, A.M. Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. Eur. J. Cell Biol. 1998, 77, 352-359.
266. Zugmaier, G.; Lippman, M.E.; Wellstein, A. Inhibition by pentosan polysulfate (pps) of heparin-binding growth factors released from tumor cells and blockage by pps of tumor growth in animals. J. Natl. Cancer Inst. 1992, 84, 1716-1724.
267. Presta, M.; Oreste, P.; Zoppetti, G.; Belleri, M.; Tanghetti, E.; Leali, D.; Urbinati, C.; Bugatti, A.; Ronca, R.; Nicoli, S.; et al. Antiangiogenic activity of semisynthetic biotechnological heparins: Low-molecular-weight-sulfated escherichia coli k5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 71-76.
268. Benelli, U.; Bocci, G.; Danesi, R.; Lepri, A.; Bernardini, N.; Bianchi, F.; Lupetti, M.; Dolfi, A.; Campagni, A.; Agen, C.; et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp. Eye Res. 1998, 67, 133-142.
269. Sakairi, N.; Kuzuhara, H.; Okamoto, T.; Yajima, M. Synthesis and biological evaluation of 2-amino-2-deoxy- and 6-amino-6-deoxy-cyclomaltoheptaose polysulfates as synergists for angiogenesis inhibition. Bioorg. Med. Chem. 1996, 4, 2187-2192.
270. Hoffman, R.; Burns, W.W., III; Paper, D.H. Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydrate l-carrageenan. Cancer Chemother. Pharmacol. 1995, 36, 325-334.
271. Zhou, H.; Roy, S.; Cochran, E.; Zouaoui, R.; Chu, C.L.; Duffner, J.; Zhao, G.; Smith, S.; Galcheva-Gargova, Z.; Karlgren, J.; et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 2011, 6, e21106.
272. Chen, J.; Avci, F.Y.; Munoz, E.M.; McDowell, L.M.; Chen, M.; Pedersen, L.C.; Zhang, L.; Linhardt, R.J.; Liu, J. Enzymatic redesigning of biologically active heparan sulfate. J. Biol. Chem. 2005, 280, 42817-42825.
273. Wang, L.; Geng, M.; Li, J.; Guan, H.; Ding, J. Studies of marine sulfated polymannuroguluronate on endothelial cell proliferation and endothelial immunity and related mechanisms. J. Pharmacol. Sci. 2003, 92, 367-373.
274. Liu, L.; Ping Li, C.; Cochran, S.; Ferro, V. Application of the four-component ugi condensation for the preparation of sulfated glycoconjugate libraries. Bioorg. Med. Chem. Lett. 2004, 14, 2221-2226.
275. Cochran, S.; Li, C.P.; Bytheway, I. An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to fgf-1 and fgf-2. ChemBioChem 2005, 6, 1882-1890.
276. Ashikari-Hada, S.; Habuchi, H.; Kariya, Y.; Itoh, N.; Reddi, A.H.; Kimata, K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J. Biol. Chem. 2004, 279, 12346-12354.
277. Urbinati, C.; Bugatti, A.; Oreste, P.; Zoppetti, G.; Waltenberger, J.; Mitola, S.; Ribatti, D.; Presta, M.; Rusnati, M. Chemically sulfated escherichia coli k5 polysaccharide derivatives as extracellular hiv-1 tat protein antagonists. FEBS Lett. 2004, 568, 171-177.
278. Watson, K.; Gooderham, N.J.; Davies, D.S.; Edwards, R.J. Interaction of the transactivating protein hiv-1 tat with sulphated polysaccharides. Biochem. Pharmacol. 1999, 57, 775-783.
279. Lu, C.X.; Li, J.; Sun, Y.X.; Qi, X.; Wang, Q.J.; Xin, X.L.; Geng, M.Y. Sulfated polymannuroguluronate, a novel anti-aids drug candidate, inhibits hiv-1 tat-induced angiogenesis in kaposi's sarcoma cells. Biochem. Pharmacol. 2007, 74, 1330-1339.
280. Sweeney, E.A.; Lortat-Jacob, H.; Priestley, G.V.; Nakamoto, B.; Papayannopoulou, T. Sulfated polysaccharides increase plasma levels of sdf-1 in monkeys and mice: Involvement in mobilization of stem/progenitor cells. Blood 2002, 99, 44-51.
281. O'Leary, R.; Rerek, M.; Wood, E.J. Fucoidan modulates the effect of transforming growth factor (tgf)-beta1 on fibroblast proliferation and wound repopulation in in vitro models of dermal wound repair. Biol. Pharm. Bull. 2004, 27, 266-270.
282. Lubineau, A.; Lortat-Jacob, H.; Gavard, O.; Sarrazin, S.; Bonnaffe, D. Synthesis of tailor-made glycoconjugate mimetics of heparan sulfate that bind ifn-gamma in the nanomolar range. Chemistry 2004, 10, 4265-4282.
283. Cassinelli, G.; Lanzi, C.; Tortoreto, M.; Cominetti, D.; Petrangolini, G.; Favini, E.; Zaffaroni, N.; Pisano, C.; Penco, S.; Vlodavsky, I.; et al. Antitumor efficacy of the heparanase inhibitor sst0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem. Pharmacol. 2013, 85, 1424-1432.
284. Waltenberger, J.; Mayr, U.; Frank, H.; Hombach, V. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J. Mol. Cell. Cardiol. 1996, 28, 1523-1529.
285. Takano, S.; Gately, S.; Neville, M.E.; Herblin, W.F.; Gross, J.L.; Engelhard, H.; Perricone, M.; Eidsvoog, K.; Brem, S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 1994, 54, 2654-2660.
286. Marchetti, D.; Reiland, J.; Erwin, B.; Roy, M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int. J. Cancer 2003, 104, 167-174.
287. Groen, H.J.; de Vries, E.G.; Wynendaele, W.; van der Graaf, W.T.; Fokkema, E.; Lechuga, M.J.; Poggesi, I.; Dirix, L.Y.; van Oosterom, A.T. Pnu-145156e, a novel angiogenesis inhibitor, in patients with solid tumors: A phase i and pharmacokinetic study. Clin. Cancer Res. 2001, 7, 3928-3933.
288. Raman, K.; Karuturi, R.; Swarup, V.P.; Desai, U.R.; Kuberan, B. Discovery of novel sulfonated small molecules that inhibit vascular tube formation. Bioorg. Med. Chem. Lett. 2012, 22, 4467-4470.
289. Rusnati, M.; Urbinati, C. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr. Pharm. Des. 2009, 15, 2946-2957.
290. Urbinati, C.; Chiodelli, P.; Rusnati, M. Polyanionic drugs and viral oncogenesis: A novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 2008, 13, 2758-2785.
291. Correia-da-Silva, M.; Sousa, E.; Pinto, M.M. Emerging sulfated flavonoids and other polyphenols as drugs: Nature as an inspiration. Med. Res. Rev. 2014, 34, 223-279.
292. Bugatti, A.; Urbinati, C.; Ravelli, C.; De Clercq, E.; Liekens, S.; Rusnati, M. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 tat and gp120 proteins. Antimicrob. Agents Chemother. 2007, 51, 2337-2345.
293. Liekens, S.; Leali, D.; Neyts, J.; Esnouf, R.; Rusnati, M.; Dell'Era, P.; Maudgal, P.C.; de Clercq, E.; Presta, M. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol. Pharmacol. 1999, 56, 204-213.
294. Zhang, F.; Zhang, Z.; Lin, X.; Beenken, A.; Eliseenkova, A.V.; Mohammadi, M.; Linhardt, R.J. Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor. Fibroblast growth factor receptor complexes. Biochemistry 2009, 48, 8379-8386.
295. Karoli, T.; Liu, L.; Fairweather, J.K.; Hammond, E.; Li, C.P.; Cochran, S.; Bergefall, K.; Trybala, E.; Addison, R.S.; Ferro, V. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (pi-88). J. Med. Chem. 2005, 48, 8229-8236.
296. Ma, J.; Xin, X.; Meng, L.; Tong, L.; Lin, L.; Geng, M.; Ding, J. The marine-derived oligosaccharide sulfate (mdos), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. PLoS ONE 2008, 3, e3774.
297. Zhang, W.; Chuang, Y.J.; Swanson, R.; Li, J.; Seo, K.; Leung, L.; Lau, L.F.; Olson, S.T. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004, 103, 1185-1191.
298. Aviezer, D.; Iozzo, R.V.; Noonan, D.M.; Yayon, A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cdna. Mol. Cell. Biol. 1997, 17, 1938-1946.
299. Van Wijk, X.M.; Thijssen, V.L.; Lawrence, R.; van den Broek, S.A.; Dona, M.; Naidu, N.; Oosterhof, A.; van de Westerlo, E.M.; Kusters, L.J.; Khaled, Y.; et al. Interfering with udp-glcnac metabolism and heparan sulfate expression using a sugar analogue reduces angiogenesis. ACS Chem. Biol. 2013, 8, 2331-2338.
300. Raman, K.; Ninomiya, M.; Nguyen, T.K.; Tsuzuki, Y.; Koketsu, M.; Kuberan, B. Novel glycosaminoglycan biosynthetic inhibitors affect tumor-associated angiogenesis. Biochem. Biophys. Res. Commun. 2011, 404, 86-89.
301. Ashikari-Hada, S.; Habuchi, H.; Kariya, Y.; Kimata, K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J. Biol. Chem. 2005, 280, 31508-31515.
302. Roghani, M.; Moscatelli, D. Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J. Biol. Chem. 1992, 267, 22156-22162.
303. Miao, H.Q.; Ishai-Michaeli, R.; Atzmon, R.; Peretz, T.; Vlodavsky, I. Sulfate moieties in the subendothelial extracellular matrix are involved in basic fibroblast growth factor sequestration, dimerization, and stimulation of cell proliferation. J. Biol. Chem. 1996, 271, 4879-4886.
304. Wang, S.; Ai, X.; Freeman, S.D.; Pownall, M.E.; Lu, Q.; Kessler, D.S.; Emerson, C.P., Jr. Qsulf1, a heparan sulfate 6-o-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc. Natl. Acad. Sci. USA 2004, 101, 4833-4838.
305. Uchimura, K.; Morimoto-Tomita, M.; Bistrup, A.; Li, J.; Lyon, M.; Gallagher, J.; Werb, Z.; Rosen, S.D. Hsulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: Effects on vegf, fgf-1, and sdf-1. BMC Biochem. 2006, 7, 2.
306. Chua, C.C.; Rahimi, N.; Forsten-Williams, K.; Nugent, M.A. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ. Res. 2004, 94, 316-323.
307. Sasisekharan, R.; Moses, M.A.; Nugent, M.A.; Cooney, C.L.; Langer, R. Heparinase inhibits neovascularization. Proc. Natl. Acad. Sci. USA 1994, 91, 1524-1528.
308. Collins, B.E.; Paulson, J.C. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr. Opin. Chem. Biol. 2004, 8, 617-625.
309. Ishwar, A.R.; Jeong, K.J.; Panitch, A.; Akkus, O. Raman spectroscopic investigation of peptide-glycosaminoglycan interactions. Appl. Spectrosc. 2009, 63, 636-641.
310. Raj, P.A.; Marcus, E.; Rein, R. Conformational requirements of suramin to target angiogenic growth factors. Angiogenesis 1998, 2, 183-199.
311. DeAngelis, P.L.; Liu, J.; Linhardt, R.J. Chemoenzymatic synthesis of glycosaminoglycans: Re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains. Glycobiology 2013, 23, 764-777.
312. Guedes, N.; Czechura, P.; Echeverria, B.; Ruiz, A.; Michelena, O.; Martin-Lomas, M.; Reichardt, N.C. Toward the solid-phase synthesis of heparan sulfate oligosaccharides: Evaluation of iduronic acid and idose building blocks. J. Org. Chem. 2013, 78, 6911-6934.
313. Freeman, C.; Liu, L.; Banwell, M.G.; Brown, K.J.; Bezos, A.; Ferro, V.; Parish, C.R. Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins. J. Biol. Chem. 2005, 280, 8842-8849.
314. Corallini, A.; Betti, M.; Rusnati, M.; Campioni, D.; Ciomei, M.; Sola, F.; Calza, N.; Zauli, G.; Presta, M.; Barbanti-Brodano, G.; et al. Characterization of the effects of two polysulfonated distamycin a derivatives, pnu145156e and pnu153429, on hiv type 1 tat protein. AIDS Res. Hum. Retrovir. 1998, 14, 1561-1571.
315. Raghuraman, A.; Mosier, P.D.; Desai, U.R. Finding a needle in a haystack: Development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s). J. Med. Chem. 2006, 49, 3553-3562.
316. Zhang, J.; Riverst, G.; Zhu, Y.; Jacobson, A.; Peyers, J.; Grundstrom, G.; Burch, P.; Hussein, S.; Marolewski, A.; Herlihy, W.; et al. Identification of inhibitors of heparin-growth factor interactions from combinatorial libraries of four-component condensation reactions. Bioorg. Med. Chem. 2001, 9, 825-836.
317. Herbert, J.M.; Cottineau, M.; Driot, F.; Pereillo, J.M.; Maffrand, J.P. Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic fgf in vitro. Biochem. Pharmacol. 1988, 37, 4281-4288.
318. Schwartsmann, G.; Sprinz, E.; Kalakun, L.; Yamagushi, N.; Sander, E.; Grivicich, I.; Koya, R.; Mans, D.R. Phase ii study of pentosan polysulfate (pps) in patients with aids-related kaposi's sarcoma. Tumori 1996, 82, 360-363.
319. Maione, T.E.; Gray, G.S.; Petro, J.; Hunt, A.J.; Donner, A.L.; Bauer, S.I.; Carson, H.F.; Sharpe, R.J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247, 77-79.
320. Yamaguchi, K.; Ogawa, K.; Katsube, T.; Shimao, K.; Konno, S.; Shimakawa, T.; Yoshimatsu, K.; Naritaka, Y.; Yagawa, H.; Hirose, K. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res. 2005, 25, 847-851.
321. Adulnirath, A.; Chung, S.W.; Park, J.; Hwang, S.R.; Kim, J.Y.; Yang, V.C.; Kim, S.Y.; Moon, H.T.; Byun, Y. Cyclic rgdyk-conjugated lmwh-taurocholate derivative as a targeting angiogenesis inhibitor. J. Control. Release 2012, 164, 8-16.
322. Leali, D.; Belleri, M.; Urbinati, C.; Coltrini, D.; Oreste, P.; Zoppetti, G.; Ribatti, D.; Rusnati, M.; Presta, M. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated escherichia coli k5 polysaccharide derivatives. J. Biol. Chem. 2001, 276, 37900-37908.
323. Rusnati, M.; Vicenzi, E.; Donalisio, M.; Oreste, P.; Landolfo, S.; Lembo, D. Sulfated k5 escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. Pharmacol. Ther. 2009, 123, 310-322.
324. Borgenstrom, M.; Jalkanen, M.; Salmivirta, M. Sulfated derivatives of escherichia coli k5 polysaccharides as modulators of fibroblast growth factor signaling. J. Biol. Chem. 2003, 278, 49882-49889.
325. Maddineni, J.; Jeske, W.P.; Baltasar, F.; Cornelli, U.; Manoni, M.; Hoppensteadt, D.A.; Fareed, J. Modulatory effects of escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: Flow cytometric analysis. Clin. Appl. Thromb. Hemost. 2006, 12, 311-317.
326. Oreste, P.; Zoppetti, G. Semi-synthetic heparinoids. In Handbook of Experimental Pharmacology; Springer: Berlin Heidelberg, Germany 2012; pp. 403-422.